NASDAQ:GLMD Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis $0.31 +0.01 (+3.29%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.30▼$0.3250-Day Range$0.27▼$0.4052-Week Range$0.26▼$1.26Volume5,640 shsAverage Volume126,877 shsMarket Capitalization$1.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Galmed Pharmaceuticals alerts: Email Address Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About Galmed Pharmaceuticals Stock (NASDAQ:GLMD)Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Read More GLMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLMD Stock News HeadlinesJuly 21, 2024 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Receives New Coverage from Analysts at StockNews.comJune 22, 2024 | investorplace.comGLMD Stock Earnings: Galmed Pharmaceuticals Reported Results for Q1 2024July 26, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.April 13, 2024 | fool.comGalmed Pharmaceuticals (NASDAQ: GLMD)April 10, 2024 | investorplace.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024April 4, 2024 | prnewswire.comGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023March 15, 2024 | markets.businessinsider.comGalmed Granted European Patent For Use Of Aramchol-Resmetirom To Treat NASH/MASH, Liver FibrosisMarch 15, 2024 | prnewswire.comGalmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisJuly 26, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.February 13, 2024 | uk.finance.yahoo.comGalmed Pharmaceuticals Ltd (GPH.BE)January 3, 2024 | uk.finance.yahoo.comGalmed Pharmaceuticals Ltd. (GPH.F)November 20, 2023 | finance.yahoo.comGalmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNovember 4, 2023 | morningstar.comGalmed Pharmaceuticals Ltd GLMDSeptember 26, 2023 | finance.yahoo.comGalmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisAugust 3, 2023 | nasdaq.comGalmed Pharmaceuticals (GLMD) Price Target Increased by 300.00% to 4.08July 14, 2023 | marketwatch.comGalmed Pharma Shares Drop 30% After Public Offering PricesJuly 14, 2023 | seekingalpha.comGalmed shares slump on pricing discounted stock and warrants offeringJuly 14, 2023 | finance.yahoo.comGalmed Pharmaceuticals Announces Pricing of $7 Million Public OfferingSee More Headlines Receive GLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/30/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GLMD CUSIPN/A CIK1595353 Webwww.galmedpharma.com Phone(723) 693-8448Fax972-3693-8447Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,910,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-48.30% Return on Assets-40.97% Debt Debt-to-Equity RatioN/A Current Ratio6.34 Quick Ratio6.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book0.11Miscellaneous Outstanding Shares5,050,000Free Float4,046,000Market Cap$1.59 million OptionableNot Optionable Beta0.69 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Allen Baharaff (Age 59)Co-Founder, President, CEO & Chairman Comp: $972.16kMr. Doron Cohen (Age 57)Chief Financial Officer Comp: $245.98kMr. Guy Nehemya (Age 39)COO & Data Protection Officer Comp: $287.04kMr. Yohai Stenzler CPA (Age 41)Chief Accounting Officer Comp: $290.57kDr. Liat Hayardeny (Age 57)Chief Scientific Officer Comp: $47.93kMs. Yael Hollander (Age 41)Vice President of Legal Affairs & Strategy Comp: $134.21kMs. Shani GanonHuman Resources ManagerDr. Tali Gorfine (Age 54)Medical Consultant Comp: $202.76kMore ExecutivesKey CompetitorsSoligenixNASDAQ:SNGXHepion PharmaceuticalsNASDAQ:HEPATFF PharmaceuticalsNASDAQ:TFFPSonoma PharmaceuticalsNASDAQ:SNOAFSD PharmaNASDAQ:HUGEView All CompetitorsInstitutional OwnershipCVI Holdings LLCSold 194,573 shares on 5/7/2024Ownership: 1.479%View All Institutional Transactions GLMD Stock Analysis - Frequently Asked Questions How have GLMD shares performed this year? Galmed Pharmaceuticals' stock was trading at $0.4550 on January 1st, 2024. Since then, GLMD stock has decreased by 31.0% and is now trading at $0.3139. View the best growth stocks for 2024 here. How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its quarterly earnings results on Thursday, May, 30th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter. When did Galmed Pharmaceuticals' stock split? Shares of Galmed Pharmaceuticals reverse split on Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Galmed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL) and Ocular Therapeutix (OCUL). This page (NASDAQ:GLMD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.